In this issue of the magazine we tackle infectious disease, whilst taking a look at what AMP 2017 has on offer this year in Salt Lake City, Utah.
Arvinas has revealed expansion plans on an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology.
Several deaths have been reported in a Phase III clinical trial run by Acorda Therapuetics for tozadenant, a drug to treat Parkinson’s disease.
The Government has appointed GlaxoSmithKline’s (GSK) president of research and development, as their new chief scientific advisor.
House Republicans have proposed eliminating billions of dollars in corporate tax credits that have played a key role in the booming “orphan drug” industry.
A new class of antiviral drugs works by causing the virus’ replication machinery to pause and backtrack, preventing the virus from efficiently replicating.
A flexible Food and Drug Administration has once again rescued a biotech company seeking a drug approval based on flawed clinical trial data.
Gilead Sciences’ gene therapy that uses a patient’s own genetically modified immune cells to treat certain types of non-Hodgkin lymphoma has been approved.
Use of arsenic trioxide could extend survival of some glioblastoma patients by three to four times historic median.
The NIH has launched a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.